Technical Analysis for XOMA - XOMA Corporation

Grade Last Price % Change Price Change
B 30.02 -0.27% -0.08
XOMA closed down 0.27 percent on Wednesday, November 20, 2024, on 76 percent of normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
NR7 Range Contraction -0.27%
Narrow Range Bar Range Contraction -0.27%
Multiple of Ten Bullish Other -0.27%
Inside Day Range Contraction -0.27%
20 DMA Resistance Bearish 0.03%
Multiple of Ten Bullish Other 0.03%
Inside Day Range Contraction 0.03%
20 DMA Resistance Bearish -0.63%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 17 hours ago
Down 1% about 17 hours ago
Possible NR7 about 17 hours ago
60 Minute Opening Range Breakdown about 21 hours ago
Rose Above Previous Day's High about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

XOMA Corporation Description

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor. Its proprietary products include gevokizumab, a human engineering (HE) antibody to interleukin-1 beta, which is Phase III studies for non-infectious uveitis and Behçet's uveitis; and Phase II studies for inflammatory acne, erosive osteoarthritis of the hand, active non-infectious anterior scleritis, and cardiovascular diseases. The company's proprietary products also comprise XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for diabetes, metabolic disorders, and other orphan indications; XOMA 3AB, a multi-antibody product, which is in Phase I trial for botulism poisoning; and preclinical programs for autoimmune, cardio-metabolic, infectious, inflammatory, ophthalmological, and oncological diseases. In addition, it develops FDC1, a perindopril arginine and amlodipine besylate, which has completed Phase III trial for hypertension; HCD122 and LFA102 programs that are in Phase I and II, and Phase I trials for hematologic tumors, breast and prostate cancers, and other undisclosed diseases; human monoclonal antibodies, which are in preclinical stage for undisclosed disease targets; and therapeutic antibodies that are in Phase II and Phase I trials for non-small cell lung cancer, solid tumors, and multiple myeloma. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; AVEO Pharmaceuticals, Inc.; UCB Celltech; and Genentech, Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Immune System Infectious Diseases Diabetes Antibodies Monoclonal Antibodies Antibody Prostate Cancer Hypertension Non Small Cell Lung Cancer Cardiovascular Disease Allergy Small Cell Lung Cancer Multiple Myeloma Vascular Disease Osteoarthritis Acne Metabolic Disorders Platform Technologies Inflammatory Uveitis Botulism Human Monoclonal Antibodies Antibody Product Non Infectious Uveitis

Is XOMA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 33.78
52 Week Low 14.33
Average Volume 25,176
200-Day Moving Average 26.21
50-Day Moving Average 28.88
20-Day Moving Average 30.47
10-Day Moving Average 30.35
Average True Range 1.51
RSI (14) 50.98
ADX 19.97
+DI 21.47
-DI 15.96
Chandelier Exit (Long, 3 ATRs) 29.25
Chandelier Exit (Short, 3 ATRs) 31.27
Upper Bollinger Bands 32.02
Lower Bollinger Band 28.93
Percent B (%b) 0.35
BandWidth 10.12
MACD Line 0.35
MACD Signal Line 0.55
MACD Histogram -0.2004
Fundamentals Value
Market Cap 344.86 Million
Num Shares 11.5 Million
EPS -2.81
Price-to-Earnings (P/E) Ratio -10.68
Price-to-Sales 53.15
Price-to-Book 2.26
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.14
Resistance 3 (R3) 31.11 30.72 30.95
Resistance 2 (R2) 30.72 30.43 30.73 30.89
Resistance 1 (R1) 30.37 30.26 30.17 30.39 30.83
Pivot Point 29.97 29.97 29.87 29.98 29.97
Support 1 (S1) 29.62 29.69 29.43 29.65 29.21
Support 2 (S2) 29.23 29.51 29.24 29.15
Support 3 (S3) 28.88 29.23 29.09
Support 4 (S4) 28.90